Description

Clinical Evidence

• A 2010 study published in the New England Journal of Medicine demonstrated that Tesamorelin significantly reduced visceral fat in HIV-infected patients with lipodystrophy.
• Follow-up trials showed improvements in IGF-1 levels, body composition, and cardiometabolic markers.
• Unlike direct GH therapy, Tesamorelin maintains normal feedback regulation, reducing the risk of long-term hormone suppression.
Tesamorelin has a half-life of approximately 20–30 minutes but exerts prolonged biological activity through GHRH receptor stimulation.

Potential Side Effects

Tesamorelin is generally well tolerated in clinical trials. Possible side effects include:
• Redness or swelling at injection site
• Mild joint pain or muscle soreness
• Increased blood sugar levels (monitoring advised in metabolic studies)
• Headache or tingling sensations
• Rare: hypersensitivity reactions or localized swelling
While side effects are typically mild, studies recommend monitoring IGF-1 levels and glucose metabolism during extended use.

Disclaimer

This peptide is intended for research use only and is not approved for non-clinical human or veterinary use outside of FDA-labeled indications. All references to clinical benefits are based on published research and regulated medical use. It must be handled by professionals in a licensed laboratory or research setting.